Surface Oncology, Inc. (SURF) Financial Analysis & Valuation | Quarter Chart
Surface Oncology, Inc. (SURF)
SURFPrice: $1.07
Fair Value: 🔒
🔒score
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosin... more
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of canc... more
Description
Shares
| Market Cap | $65.08M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Lisa McGrath |
| IPO Date | 2018-04-19 | CAGR | 0.29% |
| Employees | 35 | Website | www.surfaceoncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SURF chart loading...
Fundamentals
Technicals
| Enterprise Value | $47.45M | P/E Ratio | -0.69 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2.17 | P/B Ratio | 0.64 |
| P/CF Ratio | -1 | P/FCF Ratio | -1.08 |
| EPS | $-1.56 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -1.79% | Gross Margin | 1% |
| Operating Margin | -2.06% | Profit Margin | -2.18% |
| ROE | -0.62% | ROA | -0.41% |
| ROCE | -0.43% | Current Ratio | 7.94 |
| Quick Ratio | 7.95 | Cash Ratio | 3.13 |
| Debt/Equity | 0.6 | Interest Coverage | -36.03 |
| Altman Z Score | -6.76 | Piotroski Score | 3 |